Physician profile
Julia Kielar
NPI 1740733260
$1,246.81
in general payments reported to CMS, 2019-2025
11 companies · $611 in 2025
The $611 reported for 2025 was more than what 76% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $129 · 2023: $274 · 2024: $233 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $370.97 | 2024-2025 | Krystexxa, Tavneos, Evenity |
| Gilead Sciences, INC. | $282.36 | 2022-2024 | Biktarvy |
| Abbvie INC. | $265.37 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $151.20 | 2023-2025 | Saphnelo, Enhertu |
| Mentor Worldwide LLC | $57.69 | 2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Bayer Healthcare Pharmaceuticals INC. | $33.94 | 2025 | |
| Merck Sharp & Dohme LLC | $18.38 | 2025 | Welireg, Keytruda |
| Glaxosmithkline, LLC. | $18.24 | 2025 | Zejula, Jemperli |
| Agios Pharmaceuticals, INC. | $17.46 | 2025 | Pyrukynd |
| Eisai INC. | $16.31 | 2025 | |
| Deciphera Pharmaceuticals INC. | $14.89 | 2025 | Qinlock, Romvimza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Kielar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.